Mode
Text Size
Log in / Sign up
N/A N=75 Randomized Single-blind Treatment

Targeting HIV Retention and Improved Viral Load Through Engagement ('THRIVE')

Human Immunodeficiency Virus · Depression · Anxiety

Enrolled (actual)
75
Serious AEs
0.0%
Results posted
Oct 2025
Primary outcome: Primary: Acceptability of Enrollment and Randomization: Eligible But Declined Participation — 0; 0 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
THRIVE (Behavioral); Treatment as Usual (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Baylor College of Medicine
Primary completion
Feb 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Acceptability of Enrollment and Randomization: Eligible But Declined Participation
0; 0
PRIMARY
Acceptability of Enrollment and Randomization: Completion Sessions
28; 0
PRIMARY
Acceptability of the Intervention: 6 Month Follow-up
21; 26
PRIMARY
Acceptability of the Intervention
135.5
SECONDARY
Viral Load Improvement
12; 14
SECONDARY
Number of Patients Who Are Retained in HIV Care
13; 16

Summary

Many people with HIV infection are not consistently engaged in outpatient HIV care, and avoidance, stigma and denial contribute to poor engagement in HIV care. This project will develop and pilot test a new intervention, "THRIVE," for hospitalized persons who are out of HIV care and endorse avoidance, to improve how well they stay in outpatient HIV care after discharge. If successfully developed, the intervention will undergo large scale testing in later studies and could improve the health of persons with HIV infection and help end the HIV epidemic in the United States.

Eligibility Criteria

Inclusion Criteria

  • Hospitalized at Ben Taub Hospital, Houston, TX;
  • at least 18 years of age;
  • able to speak English or Spanish;
  • HIV infected;
  • able to provide informed consent and participate in the study (patients who are temporarily unable to participate will be followed and approached for enrollment if and when they are cognitively and physically capable of consenting and participating);
  • HIV VL>1000 c/mL;
  • never in care or currently out of HIV care, defined as not meeting the 'visit constancy' measure (≥1 completed HIV primary care visit at Thomas Street Health Center (TSHC), Houston, TX, in each of the three 4-month intervals preceding admission); or ≥2 "no shows" to HIV primary care visits at TSHC in the last year.
  • endorse one of two avoidance coping statements with the highest factor loadings on the Avoidant Coping Subscale from the Coping with HIV/AIDS scale

Exclusion Criteria

  • intending to use a source of HIV primary care other than TSHC after discharge, because their outcomes cannot be evaluated;
  • in the opinion of the primary medical team caring for the patient, likely to be discharged to an institutional setting, die in the hospital or enter hospice;
  • incarcerated or expected to be discharged to prison or jail;
  • enrolled in another research study with prospective follow-up;
  • pregnant, since pregnant women receive additional efforts to be linked and retained in care;
  • admitted with acute psychosis which would preclude informed consent or meaningful participation with the intervention.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04481373). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search